Sirolimus in Kidney Transplant Patients With Squamous Cell Skin Carcinoma

Summary

Solid organ transplant recipients (SOTR) have a 3-5x increased occurrence of cancer in contrast to the general population with basal and squamous cell skin cancer. The use of immunosuppressant or anti-rejection drugs that are needed after SOTR is known to increase the risk of developing certain kinds of cancer. The purpose of this study is to find out how well Sirolimus (also known as Rapamune) works at treating squamous cell carcinoma in renal transplant patients.

Timeline

Start

2013-04

Primary completion

2014-06

Completion

2014-06

Outcome

Outcome not reported

Stopped (Enrollment): “Poor accrual”

Drugs

Indications